Aurélie Dumont
A5072362035- PARP inhibition in cancer therapy
- BRCA gene mutations in cancer
- Ovarian cancer diagnosis and treatment
- Microtubule and mitosis dynamics
- Cancer Treatment and Pharmacology
- Lung Cancer Treatments and Mutations
- Advanced Breast Cancer Therapies
- Cancer-related Molecular Pathways
- Cancer Genomics and Diagnostics
- HER2/EGFR in Cancer Research
- Breast Cancer Treatment Studies
- Genetic factors in colorectal cancer
- Wnt/β-catenin signaling in development and cancer
- Advancements in Semiconductor Devices and Circuit Design
- Breast Lesions and Carcinomas
- Brain Metastases and Treatment
- Pharmacogenetics and Drug Metabolism
- Radio Frequency Integrated Circuit Design
- Clinical Laboratory Practices and Quality Control
- Data Quality and Management
- DNA Repair Mechanisms
- Ancient and Medieval Archaeology Studies
- Cancer therapeutics and mechanisms
- Protein Kinase Regulation and GTPase Signaling
- Skin and Cellular Biology Research
Assistance Publique – Hôpitaux de Paris
2024
Centre Oscar Lambret
2013-2023
Institut Curie
2012-2018
Université Paris Sciences et Lettres
2018
Bristol-Myers Squibb (France)
2018
Comprehensive Cancer Center Vienna
2017
Translational Research in Oncology
2013
Inserm
2012
École Nationale Supérieure des Mines de Paris
2012
AgroParisTech
2012
Breast cancers are composed of molecularly distinct subtypes with different clinical outcomes and responses to therapy. To discover potential therapeutic targets for the poor prognosis-associated triple-negative breast cancer (TNBC), gene expression profiling was carried out on a cohort 130 samples. Polo-like kinase 1 (PLK1) found be significantly overexpressed in TNBC compared other subtypes. High PLK1 confirmed by reverse phase protein tissue microarrays. In cell lines, RNAi-mediated...
Triple-negative breast cancer (TNBC) represents a subgroup of cancers (BC) associated with the most aggressive clinical behavior. No targeted therapy is currently available for treatment patients TNBC. In order to discover potential therapeutic targets, we searched protein kinases that are overexpressed in human TNBC biopsies and whose silencing cell lines causes death. A cohort including BC obtained at Institut Curie as well normal tissues has been analyzed gene-expression level. The data...
The optimal application of maintenance PARP inhibitor therapy for ovarian cancer requires accessible, robust, and rapid testing homologous recombination deficiency (HRD). However, in many countries, access to HRD is problematic the failure rate high. We developed an academic test support treatment decision-making.Genomic Instability Scar (GIScar) was through targeted sequencing a 127-gene panel determine status. GIScar trained from noninterventional study with 250 prospectively collected...
c-Yes, a member of the Src tyrosine kinase family, is found highly activated in colon carcinoma but its importance relative to c-Src has remained unclear. Here we show that, HT29 cells, silencing not c-Src, selectively leads an increase cell clustering associated with localisation β-catenin at membranes and reduction expression target genes. c-Yes induced apoptosis, inhibition growth soft-agar mouse xenografts, migration loss capacity generate liver metastases mice. Re-introduction c -Src,...
Breast cancer (BC) risk for BRCA1 and BRCA2 mutation carriers varies by genetic familial factors. About 50 common variants have been shown to modify BC carriers. All but three, were identified in general population studies. Other carrier-specific susceptibility may exist studies of so far underpowered. We conduct a novel case-only genome-wide association study comparing genotype frequencies between 60,212 cases 13,007 with or mutations. identify robust associations 2 3 carriers, P < 10-8, at...
// Sylvie Maubant 1, * , Tania Tahtouh Amélie Brisson 1 Virginie Maire Fariba Némati 2 Bruno Tesson 3 Mengliang Ye Guillem Rigaill 4, 5 Maïté Noizet Aurélie Dumont David Gentien 6 Bérengère Marty-Prouvost Leanne de Koning 7 Sardar Faisal Mahmood Didier Decaudin Francisco Cruzalegui 8 Gordon C. Tucker Sergio Roman-Roman 9 and Thierry Dubois Institut Curie, PSL Research University, Translational Department, Breast Cancer Biology Group, Paris, France Preclinical Investigation Laboratory, INSERM...
Neoadjuvant chemotherapy (NCT) using anthracyclines and taxanes is a standard treatment for locally advanced breast cancer. Efficacy of NCT however variable among patients predictive markers are expected to guide the selection who will benefit from NCT. A promising approach stand with polymorphisms located in genes encoding drug transporters, metabolizing enzymes target which can affect efficacy. Our study investigated potential 37 predict response cancer.118 women adenocarcinoma were...
Abstract Background Linking independent sources of data describing the same individuals enable innovative epidemiological and health studies but require a robust record linkage approach. We describe hybrid process to link databases from two ongoing French national studies, GEMO (Genetic Modifiers BRCA1 BRCA2 ), which focuses on identification genetic factors modifying cancer risk mutation carriers, GENEPSO (prospective cohort BRCAx carriers), environmental lifestyle factors. Methods To...
Edoxaban is a direct oral anticoagulant available in Europe but not France. Given the high tourist traffic France, understanding pharmacology of edoxaban and availability its laboratory testing seemed crucial emergency situations. The aim this work was to describe methodology for measuring anti-Xa activity edoxaban, highlighting pre-analytical analytical aspects, along with essential clinico-biological data therapeutic guidance. analysis performed using chromogenic method on STAR-Max...
536 Background: Pathological complete response (pCR) is the main prognostic factor after preoperative chemotherapy. Predictive factors of pCR are mainly histological type, hormonal status, HER2 overexpression. Single nucleotide polymorphisms (SNP) in genes encoding drug transporters, metabolizing enzymes and target can affect efficacy may explain therapeutic failures. The aim study was to identify SNPs associated with breast cancer (BC) patients (PTS) HER-2 overexpression treated sequential...
Abstract Background: Adjuvant chemotherapy (ACT) using anthracyclines and taxanes is a standard treatment for BC. Usual criteria as age, SBR grade, HER2 or hormonal status (HS), estrogen receptor (ER), triple negative BC, histological type, lymphovascular invasion (LVI), Ki67, tumor size lymph node involvement are not yet sufficient ACT decision. As SNPs located in genes involved metabolism transport of cytotoxic drugs may affect efficacy ACT, we investigated the potential 49 to predict...
<p>PDF file - 66K</p>
<p>PDF file - 122K</p>
<p>PDF file - 135K, Expression of PLK2, PLK3 and PLK4 in human breast cancers</p>
<div>Abstract<p>Breast cancers are composed of molecularly distinct subtypes with different clinical outcomes and responses to therapy. To discover potential therapeutic targets for the poor prognosis-associated triple-negative breast cancer (TNBC), gene expression profiling was carried out on a cohort 130 samples. Polo-like kinase 1 (PLK1) found be significantly overexpressed in TNBC compared other subtypes. High PLK1 confirmed by reverse phase protein tissue microarrays. In...
<div>Abstract<p>Breast cancers are composed of molecularly distinct subtypes with different clinical outcomes and responses to therapy. To discover potential therapeutic targets for the poor prognosis-associated triple-negative breast cancer (TNBC), gene expression profiling was carried out on a cohort 130 samples. Polo-like kinase 1 (PLK1) found be significantly overexpressed in TNBC compared other subtypes. High PLK1 confirmed by reverse phase protein tissue microarrays. In...
Abstract Introduction. Treatment of patients with triple-negative breast cancers (TNBCs) remains a major challenge for oncologists. Although they respond well to the current therapeutic strategies based on conventional chemotherapies, represent large proportion cancer death due high recurrence rate. Alternative treatments are needed improve survival these patients. The Wnt/beta-catenin signaling, recently reported be activated in TNBCs, may an interesting pathway target. Methods. We analyzed...
544 Background: Neoadjuvant chemotherapy (NCT) using anthracyclines and taxanes is a standard treatment for locally advanced breast cancer pathologic complete response (pCR) major prognostic factor survival. Gene polymorphisms have been identified as modulators of response. Our study investigated constitutional variants genes associated with change in the to neoadjuvant and/or patients adenocarcinoma. Methods: From November 2007 January 2012, 118 women adenocarcinoma histologically proven,...
<p>PDF file - 122K</p>
<p>PDF file - 66K</p>